RxDoctor Payments Data

Kinnari Patel, OD

Optometrist · Clarksburg, NJNPI 1851341382

Payments from drug & device makers

$5,987in general payments, 2019–2025

Across 93 payments — averaging $64.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotissue Holdings Inc.$2K
  • Kala Pharmaceuticals, Inc.$730
  • Shire North American Group Inc$721
  • Sun Pharmaceutical Industries Inc.$570
  • Lumenis, Inc$500
  • Regeneron Healthcare Solutions, Inc.$232
  • plus $2K from 18 others

What the payments were for

  • Consulting fees$1,39023%
  • Speaking & faculty fees$5008%
  • Travel & lodging$83814%
  • Food & beverage$3,25954%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,987 in reported general payments places this provider in the 95th percentile of 1,357 optometrist providers in New Jersey.

See all optometrist providers in New Jersey

Medicare billing

Part B allowed, 2024
$143,916
Medicare patients
654
Services billed
1,445

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast119$133,410
RestasisCyclosporine95$100,104
XdemvyLotilaner21$38,877
Cyclosporine54$29,694
CequaCyclosporine21$20,190
Loteprednol Etabonate62$11,015
LumiganBimatoprost18$5,620
Brimonidine Tartrate58$3,179
Latanoprost213$2,724
Travoprost11$2,375
Timolol Maleate38$1,464
MoxifloxacinMoxifloxacin Hcl28$806
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha52$651
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat34$427
Prednisolone Acetate13$420

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra$99$133,410119 claims
AbbVieRestasis, Lumigan$136$105,724113 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$54$38,87721 claims
Sun Pharmaceutical Industries Inc.Cequa$570$20,19021 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$15$11,01562 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,357 optometrist providers in New Jersey.

Other optometrist in Clarksburg

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →